Compare Koken Ltd. with Similar Stocks
Dashboard
1
High Debt company with Weak Long Term Fundamental Strength
2
The company has declared positive results for the last 2 consecutive quarters
3
With ROCE of 7.53%, it has a very attractive valuation with a 0.79 Enterprise value to Capital Employed
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 9,738 Million (Micro Cap)
12.00
NA
0.08%
0.22
6.42%
0.71
Revenue and Profits:
Net Sales:
2,820 Million
(Quarterly Results - Mar 2026)
Net Profit:
143 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.95%
0%
6.95%
6 Months
7.35%
0%
7.35%
1 Year
21.39%
0%
21.39%
2 Years
21.17%
0%
21.17%
3 Years
21.99%
0%
21.99%
4 Years
14.14%
0%
14.14%
5 Years
2.27%
0%
2.27%
Koken Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.15%
EBIT Growth (5y)
2.33%
EBIT to Interest (avg)
24.25
Debt to EBITDA (avg)
1.82
Net Debt to Equity (avg)
0.16
Sales to Capital Employed (avg)
0.58
Tax Ratio
26.32%
Dividend Payout Ratio
27.80%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.16%
ROE (avg)
6.43%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
0.75
EV to EBIT
10.54
EV to EBITDA
7.94
EV to Capital Employed
0.79
EV to Sales
1.13
PEG Ratio
0.45
Dividend Yield
0.07%
ROCE (Latest)
7.53%
ROE (Latest)
6.42%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
2,819.80
4,413.10
-36.10%
Operating Profit (PBDIT) excl Other Income
355.30
839.40
-57.67%
Interest
18.10
16.10
12.42%
Exceptional Items
0.00
0.00
Consolidate Net Profit
143.30
520.80
-72.48%
Operating Profit Margin (Excl OI)
88.30%
164.10%
-7.58%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -36.10% vs 87.54% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -72.48% vs 637.68% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
11,857.10
10,762.40
10.17%
Operating Profit (PBDIT) excl Other Income
1,688.10
1,451.00
16.34%
Interest
59.70
47.50
25.68%
Exceptional Items
0.00
31.60
-100.00%
Consolidate Net Profit
885.30
722.10
22.60%
Operating Profit Margin (Excl OI)
107.20%
93.80%
1.34%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 10.17% vs 1.66% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 22.60% vs 3.00% in Dec 2024
About Koken Ltd. 
Koken Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






